BR112019018687A2 - métodos de tratamento e/ou prevenção da ceratose actínica - Google Patents

métodos de tratamento e/ou prevenção da ceratose actínica Download PDF

Info

Publication number
BR112019018687A2
BR112019018687A2 BR112019018687-5A BR112019018687A BR112019018687A2 BR 112019018687 A2 BR112019018687 A2 BR 112019018687A2 BR 112019018687 A BR112019018687 A BR 112019018687A BR 112019018687 A2 BR112019018687 A2 BR 112019018687A2
Authority
BR
Brazil
Prior art keywords
days
subject
affected area
fact
application
Prior art date
Application number
BR112019018687-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Rudolf KWAN Min-fun
Yiu-Nam Lau Johnson
Douglas Kramer E.
Lawrence Cutler David
Fang Jane
Original Assignee
Athenex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019018687(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Athenex, Inc. filed Critical Athenex, Inc.
Publication of BR112019018687A2 publication Critical patent/BR112019018687A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
BR112019018687-5A 2017-03-10 2018-03-12 métodos de tratamento e/ou prevenção da ceratose actínica BR112019018687A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
US62/469,889 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (1)

Publication Number Publication Date
BR112019018687A2 true BR112019018687A2 (pt) 2020-04-07

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018687-5A BR112019018687A2 (pt) 2017-03-10 2018-03-12 métodos de tratamento e/ou prevenção da ceratose actínica

Country Status (22)

Country Link
US (3) US10617693B2 (https=)
EP (2) EP3592355B1 (https=)
JP (3) JP7502863B2 (https=)
KR (2) KR20240090837A (https=)
CN (1) CN110891575A (https=)
AU (2) AU2018231144B2 (https=)
BR (1) BR112019018687A2 (https=)
CA (1) CA3055938A1 (https=)
DK (1) DK3592355T3 (https=)
ES (1) ES3060528T3 (https=)
FI (1) FI3592355T3 (https=)
HR (1) HRP20260155T1 (https=)
IL (1) IL269182B2 (https=)
LT (1) LT3592355T (https=)
MX (2) MX387658B (https=)
NZ (1) NZ757105A (https=)
PL (1) PL3592355T3 (https=)
PT (1) PT3592355T (https=)
RS (1) RS67713B1 (https=)
TW (1) TWI841523B (https=)
WO (1) WO2018165647A1 (https=)
ZA (1) ZA202100106B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
US11752156B2 (en) * 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
US20220305021A1 (en) * 2019-06-05 2022-09-29 Athenex, Inc. Methods of treating and/or preventing psoriasis
CA3205857A1 (en) * 2021-01-21 2022-07-28 Michael MOLYNEAUX Compositions and methods for treatment of skin cancers
CN120152984A (zh) * 2023-10-13 2025-06-13 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP2041071B1 (en) 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
US7538252B2 (en) 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
EP2155681B1 (en) 2007-05-17 2018-05-02 Athenex, Inc. Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
WO2010080345A1 (en) * 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
AU2018231144A1 (en) 2019-10-03
US10617693B2 (en) 2020-04-14
MX387658B (es) 2025-03-18
LT3592355T (lt) 2026-02-25
US20230172942A1 (en) 2023-06-08
ES3060528T3 (en) 2026-03-26
JP2020510042A (ja) 2020-04-02
RS67713B1 (sr) 2026-02-27
NZ757105A (en) 2026-02-27
RU2019131757A (ru) 2021-04-12
JP2023015269A (ja) 2023-01-31
AU2018231144B2 (en) 2023-12-21
TW201842913A (zh) 2018-12-16
IL269182B1 (en) 2023-07-01
WO2018165647A1 (en) 2018-09-13
JP7502863B2 (ja) 2024-06-19
FI3592355T3 (fi) 2026-02-13
PT3592355T (pt) 2026-02-03
EP4659740A2 (en) 2025-12-10
EP3592355A4 (en) 2021-01-06
CA3055938A1 (en) 2018-09-13
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
AU2024201828B2 (en) 2026-02-19
EP3592355A1 (en) 2020-01-15
TWI841523B (zh) 2024-05-11
PL3592355T3 (pl) 2026-04-07
KR20240090837A (ko) 2024-06-21
AU2024201828A1 (en) 2024-05-02
DK3592355T3 (da) 2026-02-16
EP3592355B1 (en) 2025-12-10
HRP20260155T1 (hr) 2026-03-27
MX2019010707A (es) 2020-01-15
KR20190141661A (ko) 2019-12-24
IL269182B2 (en) 2023-11-01
RU2019131757A3 (https=) 2021-05-31
US20180256589A1 (en) 2018-09-13
US11497750B2 (en) 2022-11-15
ZA202100106B (en) 2022-08-31
JP2025029010A (ja) 2025-03-05
EP4659740A3 (en) 2026-02-18
IL269182A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
BR112019018687A2 (pt) métodos de tratamento e/ou prevenção da ceratose actínica
Arndt et al. Manual of dermatologic therapeutics
ES2585884T3 (es) Regímenes terapéuticos
HU211689A9 (en) Treatment of disease employing hyaluronic acid and nsaids
Pasricha et al. Treatment of skin diseases
US8741956B2 (en) Treatment of pain with topical diclofenac
Moggio et al. A randomized split-face clinical trial analyzing daylight photodynamic therapy with methyl aminolaevulinate vs ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and the scalp
JP7096332B2 (ja) 腫瘍処置誘導性の経口胃腸粘膜炎の予防および／または処置における使用のための組成物
BR112019024116A2 (pt) Use da coenzima q10 formulações no tratamento e prevenção de epidermólise bolhosa
BR122025000862A2 (pt) Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica
BR112021001873A2 (pt) composição para o uso na prevenção e/ou tratamento da mucosa genitourinária
RU2805929C2 (ru) Способы лечения и/или предотвращения актинического кератоза
Noushin et al. Safety and efficacy of 30% hydrogen peroxide in seborrheic keratoses–A prospective and interventional study
Silpa‐archa et al. Narrow‐band ultraviolet B phototherapy in vitiligo
HK40020549A (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
HK40020549B (en) Kx2‑391/kx‑01 for use in the treatment of actinic keratosis
RU2426567C1 (ru) Способ профилактики и/или лечения фоновых и предраковых заболеваний органов женской половой сферы
Singh et al. Acne & Scars
Sundaresan et al. Sirunya Silapunt, MD
TW202112379A (zh) 治療及／或預防乾癬之方法
Nisbet MANAGING THE SIDE EFFECTS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: ATNX SPV, LLC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09S Decision of refusal: publication cancelled [chapter 9.2.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2813 DE 03/12/2024 POR TER SIDO INDEVIDA.

B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025000862-1 PROTOCOLO 870250003745 EM 16/01/2025 15:46.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]